BridgeBio
BridgeBio Pharma (NASDAQ: BBIO) is a publicly-traded biopharmaceutical company developing precision medicines for genetic diseases, with three FDA-approved therapies including Attruby for ATTR-CM and a late-stage pipeline targeting LGMD2I/R9, ADH1, and achondroplasia.
- Company typePublic
- Founded2015
- HeadquartersPalo Alto, United States
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What BridgeBio does
BridgeBio Pharma, Inc. is a publicly-traded biopharmaceutical company (NASDAQ: BBIO) founded in 2015 and headquartered in Palo Alto, California, that develops precision medicines for patients with genetic diseases and genetically defined cancers. The company operates a decentralized hub-and-spoke model in which autonomous teams pursue individual genetic conditions while a central hub supplies clinical, regulatory, and commercial infrastructure, and has secured three FDA approvals: Attruby (acoramidis, a selective near-complete TTR stabilizer for transthyretin amyloid cardiomyopathy), BEYONTTRA (the same molecule marketed outside the US), and NULIBRY (fosdenopterin for molybdenum cofactor deficiency type A). Its late-stage pipeline includes BBP-418 for limb-girdle muscular dystrophy type 2I/R9 (NDA accepted for priority review, target action date November 27, 2026), encaleret for autosomal dominant hypocalcemia type 1, and oral infigratinib for achondroplasia, each addressing orphan indications projected to contribute to a stated $8 billion portfolio peak sales potential.
BridgeBio monetizes primarily through direct US product sales via a specialty sales force and specialty pharmacy network, supplemented by the ForgingBridges patient access program and Patient Access Liaisons. Ex-US commercial rights are licensed rather than built directly: Bayer holds exclusive European marketing rights for acoramidis in a deal valued at up to $310 million, and DKSH was signed in June 2026 for end-to-end distribution in Australia, Singapore, South Korea, and Taiwan. Full-year 2025 revenue reached $502.1 million (Attruby contributing $362.4 million) with Q1 2026 revenue of $194.52 million, reflecting accelerating launch momentum (Q4 2025 Attruby grew 35% sequentially and 355% year-over-year, capturing over 25% ATTR-CM market share across 1,632 prescribers).
The company serves patients with rare genetic diseases, the cardiologists, neurologists, and rare-disease specialists who treat them, payors and specialty pharmacies that reimburse and dispense the therapies, and patient advocacy organizations such as the Muscular Dystrophy Association. Capital structure is unusually active for a commercial-stage biotech of this size, with $1.25 billion of strategic financing from Blue Owl Capital and CPP Investments in January 2024 and $550 million of 0.75% convertible senior notes issued in January 2026 to refinance existing 2027 maturities and fund pipeline launches. Subsidiary structure includes wholly-owned operating units Calcilytix, Eidos, ML Bio Solutions, QED Therapeutics, and BridgeBio Oncology Therapeutics, plus BridgeBio Europe BV, supporting a multi-indication development engine that targets six approved products by the end of the company's first decade.
BridgeBio firmographics
Firmographics- Name
- BridgeBio
- Legal name
- BridgeBio Pharma, Inc.
- Website
- https://bridgebio.com
- Company type
- Public
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- BridgeBio Pharma (NASDAQ: BBIO) is a publicly-traded biopharmaceutical company developing precision medicines for genetic diseases, with three FDA-approved therapies including Attruby for ATTR-CM and a late-stage pipeline targeting LGMD2I/R9, ADH1, and achondroplasia.
- Ownership category
- akta.pro rank
BridgeBio industry classification
Industry- Product category
- Rare Disease Pharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (6215)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Microbiome-Derived Metabolite Therapeutics (postbiotics) (HLAAAFAB)
- akta.pro secondary industry
- Microbiome Modulating Small Molecules & Antibiotic Alternatives (HLAAAFAG)
Keywords
Where BridgeBio is headquartered
LocationHeadquarters
- HQ city
- Palo Alto
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
BridgeBio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain
Revenue model
- Product Sales - Attruby (acoramidis): BridgeBio generates revenue from direct product sales of its FDA-approved drugs. Attruby for ATTR-CM generated $362.4 million in full-year 2025 revenue and $146 million in Q4 2025 alone, representing 35% sequential quarterly growth with accelerating new patient additions.
- Product Sales - NULIBRY (fosdenopterin): Sales of NULIBRY for MoCD type A, one of BridgeBio's approved medicines.
- Licensing Royalties - European Partnership: Bayer holds exclusive European licensing rights for acoramidis (marketed as BEYONTTRA in Europe), generating potential licensing and royalty revenue for BridgeBio. Deal valued at up to $310 million.
- Convertible Notes and Equity Offerings: BridgeBio raised $632.5 million through convertible notes in January 2026 and completed a $550 million convertible notes offering at 0.75% interest rate in January 2026 to refinance existing debt and support growth.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Other | Patient assistance programs for prescribed BridgeBio medicines |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels7 records
BridgeBio product offering
Product offeringCore offering
BridgeBio is a commercial-stage biopharmaceutical company that develops, manufactures, and commercializes precision medicines for genetic diseases. It sells two FDA-approved drugs—Attruby (acoramidis) for transthyretin amyloid cardiomyopathy and NULIBRY (fosdenopterin) for molybdenum cofactor deficiency type A—and advances a late-stage pipeline including BBP-418 for LGMD2I/R9, encaleret for ADH1, infigratinib for achondroplasia, and BBP-812 gene therapy for Canavan Disease.
Product overview
BridgeBio is a biopharmaceutical company focused on developing medicines for genetic diseases. The company operates a hub-and-spoke model with approved medicines including Attruby (acoramidis) for ATTR-CM and NULIBRY (fosdenopterin) for MoCD type A. The late-stage pipeline includes BBP-418 for LGMD2I/R9 (NDA submitted), encaleret for ADH1, and infigratinib for achondroplasia. Additional programs target hypochondroplasia, Canavan disease, and ATTRv. Patient support is provided through the ForgingBridges program, and diagnostic services include a genetic testing program for ADH1 and hypoparathyroidism in partnership with Prevention Genetics. The company has received 3 FDA approvals and projects $8 billion peak year sales potential across its portfolio.
Differentiator
Problem solved
Functional benefit
Brands
- Attruby: FDA-approved TTR stabilizer for ATTR-CM (transthyretin amyloid cardiomyopathy)
- NULIBRY
- ForgingBridges
- BEYONTTRA
Products and services
- Attruby (acoramidis) FDA-approved selective near-complete TTR stabilizer for treating transthyretin amyloid cardiomyopathy (ATTR-CM) in adults. Marketed as BEYONTTRA outside the U.S. Achieved $362.4M in 2025 revenue with 25%+ market share. For patients with ATTR-CM and prescribing cardiologists and rare disease specialists.
- NULIBRY (fosdenopterin) Approved treatment for molybdenum cofactor deficiency (MoCD) type A, a rare genetic condition. For patients with MoCD type A and their metabolic specialists.
- BBP-418 Investigational oral treatment for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). Demonstrated 5% increase in predicted pulmonary volume versus placebo in Phase 3 FORTIFY trial. Potential first approved therapy for any form of LGMD. For patients with LGMD2I/R9 and neuromuscular specialists.
- Encaleret Investigational treatment for autosomal dominant hypocalcemia type 1 (ADH1), a genetic condition affecting calcium regulation. Positive Phase 3 CALIBRATE trial results. For patients with ADH1 and endocrinologists.
- Infigratinib Oral FGFR3 inhibitor for achondroplasia and hypochondroplasia. Phase 3 PROPEL 3 trial showed +2.10 cm/year improvement in annualized height velocity (largest ever in randomized controlled trials for the condition) and first statistical significance in body proportionality. For children with achondroplasia/hypochondroplasia and pediatric endocrinologists.
- BBP-812 Gene therapy for Canavan Disease, an autosomal recessive leukodystrophy. Currently in Phase 1/2 CANaspire clinical trial. For patients with Canavan Disease and pediatric neurologists.
- ForgingBridges Patient Support Program Patient access program providing personalized support including insurance navigation, financial assistance coordination, specialty pharmacy coordination, and ongoing treatment support through Patient Access Liaisons (PALs). For patients prescribed BridgeBio medicines and their healthcare providers.
- DetectHypopara Genetic Testing Program No-cost genetic testing program for ADH1 and hypoparathyroidism, offered in partnership with Prevention Genetics (part of Exact Sciences). Includes at-home test kits and on-demand mobile testing services. For patients suspected of ADH1 or hypoparathyroidism and their healthcare providers.
Quantifiable outcome
- Attruby demonstrated 34% statistically significant reduction in cardiovascular hospitalization versus Pfizer's tafamidis
- +5 more outcomes
Companies that use BridgeBio
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
BridgeBio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
BridgeBio partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- DKSHcoreDKSH has entered a strategic distribution partnership with BridgeBio to support regulatory evaluation and potential patient access to a Transthyretin Stabilizer for ATTR-CM in Australia, Singapore, South Korea, and Taiwan. Under the agreement, DKSH is responsible for end-to-end distribution and commercialization of the treatment, leveraging its integrated commercial platform across these Asia Pacific markets.
- Muscular Dystrophy Association (MDA)coreMDA received $100,000 in funding from BridgeBio to improve multidisciplinary care for people with limb-girdle muscular dystrophy in the U.S. The grants support initiatives at Stanford Health Care and the University of Minnesota to enhance care coordination, accessibility, and long-term disease management.
- BlackDoctorminorBridgeBio partnered with BlackDoctor and HealthyWomen to publish a survey during Women's Health Month revealing that 73% of Black women respondents had never heard of ATTR-CM, with 95% never screened. The organizations call for expanded culturally relevant education and earlier screening.
- Bayer AGcoreBayer AG secured exclusive European marketing rights for acoramidis from BridgeBio in a deal valued at up to $310 million. Bayer leverages its cardiovascular infrastructure to introduce the oral treatment across Europe. Acoramidis is marketed as BEYONTTRA in Europe and other regions.
- PreventionGeneticsminorBridgeBio partners with PreventionGenetics (part of Exact Sciences) for the DetectHypopara sponsored genetic testing program, providing no-cost testing for ADH1 and hypoparathyroidism to learn more about genetic causes and support clinical management.
Scale indicators11 records
Recent moves11 records
Expansion highlights5 records
BridgeBio competitors and assessment
Company assessmentDirect peers
- Pfizer: Direct competitor in ATTR-CM with tafamidis (Vyndamax/Vyndaqel), the entrenched standard-of-care that BridgeBio's Attruby is taking share from. Comparable rare-disease cardiovascular commercial franchise and a useful benchmark for payor access dynamics.
- Alnylam Pharmaceuticals: Direct ATTR competitor via patisiran (Onpattro) and vutrisiran (Amvuttra), both RNAi therapeutics approved for ATTR amyloidosis. Operates a similar hub-and-spoke rare-disease model and competes for the same cardiologist prescriber base as Attruby.
- Ionis Pharmaceuticals: Competitor in ATTR amyloidosis with eplontersen (Wainua) and a long history of antisense therapeutics for genetic and rare neurological diseases. Closely comparable antisense/RNA platform approach to rare genetic diseases.
- BioMarin Pharmaceutical: Pure-play rare genetic disease biopharma with a multi-asset portfolio spanning enzyme replacement and small-molecule therapies. Most directly comparable business model: hub of approved rare-disease products plus late-stage pipeline for genetic conditions.
- Ultragenyx Pharmaceutical: Focused exclusively on rare genetic diseases with a portfolio spanning metabolic, skeletal, and neuromuscular disorders — directly overlapping BridgeBio's achondroplasia, LGMD, and hypoparathyroidism indications. Comparable hub-and-spoke rare-disease commercial approach.
Broad incumbents
- Alexion / AstraZeneca Rare Disease: Established rare-disease franchise within AstraZeneca spanning complement-mediated, metabolic, and neurologic genetic conditions. Larger incumbent operating in overlapping categories (neuromuscular, metabolic) with a broader commercial reach than BridgeBio.
- Vertex Pharmaceuticals: Profitable rare-disease leader anchored by the cystic fibrosis franchise, now expanding into sickle cell, pain, and gene-editing therapies. Sets the bar on capital-efficient rare-disease commercialization and rare-genetic-disease pipeline productivity.
- Regeneron Pharmaceuticals: Large-cap biotech with a substantial genetic medicines franchise (Eylea, Dupixent, Libtayo) and active investment in gene-therapy and RNAi approaches. Comparable mix of internal pipeline and external partnerships across rare and serious diseases.
Emerging players
- Intellia Therapeutics: In vivo CRISPR/Cas9 gene-editing company targeting ATTR amyloidosis (NTLA-2002) and other genetic diseases. Direct future competitor in ATTR-CM and adjacent to BridgeBio's broader gene-therapy work (BBP-812 in Canavan Disease).
- Moderna: mRNA platform company with rare-disease programs emerging from its post-COVID pipeline diversification. Comparable in pursuing novel modalities for genetic and rare conditions, though at a much earlier commercial stage in rare disease.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
BridgeBio social profiles
Digital presenceBridgeBio financial estimates
Financial estimateRevenue estimate
Valuation estimate
BridgeBio leadership team
Management profileNumber of profiles
Profiles16 records
BridgeBio subsidiaries and ownership
Company hierarchySubsidiaries6 records
BridgeBio funding detail
Funding detailFunding overview
Funding rounds18 records
Investors15 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BridgeBio M&A and investment
M&A and investmentM&A1 record
Investments5 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BridgeBio
What does BridgeBio do?
BridgeBio is a commercial-stage biopharmaceutical company that develops, manufactures, and commercializes precision medicines for genetic diseases. It sells two FDA-approved drugs—Attruby (acoramidis) for transthyretin amyloid cardiomyopathy and NULIBRY (fosdenopterin) for molybdenum cofactor deficiency type A—and advances a late-stage pipeline including BBP-418 for LGMD2I/R9, encaleret for ADH1, infigratinib for achondroplasia, and BBP-812 gene therapy for Canavan Disease.
Is BridgeBio a public or private company?
BridgeBio is a public company. It is classified as public and is currently operating.
When was BridgeBio founded?
BridgeBio was founded in 2015. It employs 501 to 1,000 people.
Where is BridgeBio based?
BridgeBio is headquartered in Palo Alto, United States, in the North America region.
How does BridgeBio make money?
Four revenue lines are on record. Product Sales - Attruby (acoramidis) is the primary driver. The others are product Sales - NULIBRY (fosdenopterin), licensing Royalties - European Partnership and convertible Notes and Equity Offerings.
Who are BridgeBio's main competitors?
Direct peers on record are Pfizer, Alnylam Pharmaceuticals, Ionis Pharmaceuticals, BioMarin Pharmaceutical and Ultragenyx Pharmaceutical. Broad incumbents are Alexion / AstraZeneca Rare Disease, Vertex Pharmaceuticals and Regeneron Pharmaceuticals. Emerging players are Intellia Therapeutics and Moderna.
Does BridgeBio have an API?
No public API is recorded for BridgeBio.
What industry is BridgeBio in?
BridgeBio's product category is Rare Disease Pharmaceuticals. Its primary akta.pro industry code is HLAAAFAB, Microbiome-Derived Metabolite Therapeutics (postbiotics), with a secondary code of HLAAAFAG, Microbiome Modulating Small Molecules & Antibiotic Alternatives. Its NAICS code is 325414 and its SIC code is 2836.